Systemic Sclerosis (Scleroderma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500

Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle  pains,  joint  pain  and  swelling,  ulcers  occurring  on  fingertips,  bloating  of  the  tummy  and diarrhea or constipation. Treatment includes antibiotic, pain relievers and immunosuppressant. Global Markets Direct’s report features investigational drugs from across globe.

The Systemic Sclerosis (Scleroderma) – Drugs In Development research report provides a comprehensive overview on  the therapeutics   under   development   for   Systemic   Sclerosis   (Scleroderma),   complete   with   analysis   by   stage   of development,  drug  target,  mechanism  of  action (MoA),  route  of  administration (RoA) and molecule  type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and  press  releases.  Additionally, the report provides  an  overview  of  key  players  involved  in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects.

Key targets in the Systemic Sclerosis (Scleroderma) Pipeline Drugs Market

The key targets in the Systemic Sclerosis (Scleroderma) pipeline drugs market are Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2, Nuclear Factor Erythroid 2 Related Factor 2, Bifunctional Glutamate/Proline tRNA Ligase, Cannabinoid Receptor 2, Cells Expressing B Lymphocyte Antigen CD19, and Endothelin 1 Receptor.

Systemic Sclerosis (Scleroderma) Pipeline Drugs Market Analysis, by Targets

Systemic Sclerosis (Scleroderma) Pipeline Drugs Market Analysis, by Targets

For more target insights, download a free report sample

Key MoA in the Systemic Sclerosis (Scleroderma) Pipeline Drugs Market

The key mechanisms of action in the Systemic Sclerosis (Scleroderma) pipeline drugs market are Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 inhibitor, Nuclear Factor Erythroid 2 Related Factor 2 inhibitor, Bifunctional Glutamate/Proline tRNA Ligase inhibitor, Cannabinoid Receptor 2 inhibitor, Cells Expressing B Lymphocyte Antigen CD19 inhibitor, and Endothelin 1 Receptor inhibitor.

Systemic Sclerosis (Scleroderma) Pipeline Drugs Market Analysis, by MoA

Systemic Sclerosis (Scleroderma) Pipeline Drugs Market Analysis, by MoA

To get more insights on key MoA, download a free report sample

Key RoA in the Systemic Sclerosis (Scleroderma) Pipeline Drugs Market

The key routes of administration in the Systemic Sclerosis (Scleroderma) pipeline drugs market are oral, intravenous, parenteral, intramuscular, topical, ophthalmic, intravenous drip, intradermal, hemodialysis, and subcutaneous.

Systemic Sclerosis (Scleroderma) Pipeline Drugs Market Analysis, by RoA

Systemic Sclerosis (Scleroderma) Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free report sample

Key Molecule Types in the Systemic Sclerosis (Scleroderma) Pipeline Drugs Market

The key molecule types in the Systemic Sclerosis (Scleroderma) pipeline drugs market are Monoclonal Antibody, Small Molecule, Recombinant Protein, Fusion Protein, Cell Therapy, Synthetic Peptide, and Biologic among others.

Systemic Sclerosis (Scleroderma) Pipeline Drugs Market, by Molecule Type

Systemic Sclerosis (Scleroderma) Pipeline Drugs Market, by Molecule Type

To get more insights on key molecule types, download a free report sample

Major companies in the Systemic Sclerosis (Scleroderma) pipeline drugs market

The major companies in the Systemic Sclerosis (Scleroderma) pipeline drugs market are Horizon Therapeutics Plc, Castle Creek Biosciences Inc, Chugai Pharmaceutical Co Ltd, Pfizer Inc, A. Menarini Industrie Farmaceutiche Riunite Srl, Acceleron Pharma Inc, Accuitis Pharmaceuticals Inc, AKL Research and Development Ltd, Allysta Pharmaceuticals Inc, and Amgen Inc among others.

Systemic Sclerosis (Scleroderma) Pipeline Drugs Market, by Major Companies

Systemic Sclerosis (Scleroderma) Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Market report overview

Key targets Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2, Nuclear Factor Erythroid 2 Related Factor 2, Bifunctional Glutamate/Proline tRNA Ligase, Cannabinoid Receptor 2, Cells Expressing B Lymphocyte Antigen CD19, and Endothelin 1 Receptor
Key mechanism of action Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 inhibitor, Nuclear Factor Erythroid 2 Related Factor 2 inhibitor, Bifunctional Glutamate/Proline tRNA Ligase inhibitor, Cannabinoid Receptor 2 inhibitor, Cells Expressing B Lymphocyte Antigen CD19 inhibitor, and Endothelin 1 Receptor inhibitor
Key routes of administration Oral, Intravenous, Parenteral, Intramuscular, Topical, Ophthalmic, Intravenous Drip, Intradermal, Hemodialysis, and Subcutaneous
Key molecule types Monoclonal Antibody, Small Molecule, Recombinant Protein, Fusion Protein, Cell Therapy, Synthetic Peptide, and Biologic
Key companies Horizon Therapeutics Plc, Castle Creek Biosciences Inc, Chugai Pharmaceutical Co Ltd, Pfizer Inc, A. Menarini Industrie Farmaceutiche Riunite Srl, Acceleron Pharma Inc, Accuitis Pharmaceuticals Inc, AKL Research and Development Ltd, Allysta Pharmaceuticals Inc, and Amgen Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma)
  • The pipeline guide reviews pipeline therapeutics for Systemic Sclerosis (Scleroderma) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Systemic Sclerosis (Scleroderma) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Systemic Sclerosis (Scleroderma) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Systemic Sclerosis (Scleroderma)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Systemic Sclerosis (Scleroderma)
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

A. Menarini Industrie Farmaceutiche Riunite Srl
Acceleron Pharma Inc
Accuitis Pharmaceuticals Inc
AKL Research and Development Ltd
Allysta Pharmaceuticals Inc
Amgen Inc
AnaMar AB
Annji Pharmaceutical Co Ltd
APIE Therapeutics Inc
arGentis Pharmaceuticals LLC
Aryogen Pharmed Co
AstraZeneca Plc
Atlantic Healthcare Plc
Aurora Research Institute LLC
Avotres Inc
Beijing Toll Biotech Co Ltd
Biogen Inc
Biomendics LLC
Blade Therapeutics Inc
BriaCell Therapeutics Corp
Bristol-Myers Squibb Co
Cantargia AB
Castle Creek Biosciences Inc
Celdara Medical LLC
Centessa Pharmaceuticals Plc
Certa Therapeutics Pty Ltd
Chemomab Therapeutics Ltd
Chugai Pharmaceutical Co Ltd
Civi Biopharma Inc
CohBar Inc
Corbus Pharmaceuticals Inc
Coya Therapeutics Inc
CSL Ltd
Cumberland Pharmaceuticals Inc
Cureveda LLC
D&D Pharmatech Co Ltd
Daewoong Pharmaceutical Co Ltd
Emerald Health Sciences Inc
FibroBiologics LLC
Foresee Pharmaceuticals Co Ltd
Fresenius Kabi SwissBioSim GmbH
Galapagos NV
Galecto Inc
Genentech USA Inc
GenKyoTex SA
Genmab AS
Genrix (Shanghai) Biopharmaceutical Co Ltd
Gesynta Pharma AB
Gilead Sciences Inc
GlaxoSmithKline Plc
GNI Group Ltd
Horizon Therapeutics Plc
iBio Inc
Ichnos Sciences Inc
Iltoo Pharma
ImmuneMed Inc
Johnson & Johnson
Kadmon Holdings Inc
Leadiant Biosciences Inc
LightOx Ltd
Link Genomics Inc
Luminary Therapeutics Inc
Mallinckrodt Plc
MDI Therapeutics Inc
Mitsubishi Tanabe Pharma Corp
Ono Pharmaceutical Co Ltd
Opsidio LLC
Panorama Researchama Research
Patagonia Pharmaceuticals LLC
PDX Pharmaceuticals LLC
Peptinov SAS
Pfizer Inc
Prometheus Biosciences Inc
RadBio
Recursion Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Resolys Bio Inc
Ribomic Inc
Riptide Bioscience Inc
Seagen Inc
Shanghai YaKe Biotechnology Co Ltd
Signablok Inc
Takeda Pharmaceutical Co Ltd
Talaris Therapeutics Inc
Thirona Bio Inc
Timber Pharmaceuticals Inc
TRACON Pharmaceuticals Inc
Tvardi Therapeutics Inc
Unity Biotechnology Inc
Vicore Pharma AB
Welichem Biotech Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Systemic Sclerosis (Scleroderma) – Overview

Systemic Sclerosis (Scleroderma) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Systemic Sclerosis (Scleroderma) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Systemic Sclerosis (Scleroderma) – Companies Involved in Therapeutics Development

Systemic Sclerosis (Scleroderma) – Drug Profiles

Mar 14, 2022: Chemomab reports on two scientific presentations that support the potential therapeutic utility of CM-101 in Systemic Sclerosis

Mar 01, 2022: Cantargia reports positive preclinical efficacy data for CAN10 demonstrating anti-fibrotic and anti-inflammatory effects in systemic sclerosis

Dec 15, 2021: Kyowa Kirin announces application for partial change of approved indication of LUMICEF for Systemic Sclerosis in Japan

Dec 13, 2021: Cantargia reports positive results for CAN10 antibody in preclinical systemic sclerosis model

Dec 07, 2021: Prometheus Biosciences reports positive topline phase 1 data on lead therapeutic candidate PRA023; expands indications to include Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

Dec 02, 2021: Emerald Health Pharmaceuticals’ novel drug candidate demonstrates significant anti-inflammatory and anti-fibrotic activity in multi-organ fibrosis preclinical model

Nov 08, 2021: Cantargia reports progress in manufacturing process development and provides update on clinical trial preparations for CAN10

Oct 14, 2021: Blade Therapeutics announces FDA orphan drug designation granted to Cudetaxestat for treatment of systemic sclerosis

Jun 14, 2021: Gesynta Pharma announces significant progress across development program for first-in-class drug candidate GS-248

May 24, 2021: Daewoong Pharmaceutical’s fibrosis drug ‘DWN12088’ additionally designated as an orphan drug by the US FDA

Apr 01, 2021: Kadmon doses first patient in open-label phase 2 clinical trial of Belumosudil in systemic sclerosis

Mar 31, 2021: Phase-2 clinical trial of MT-7117 initiated in the U.S., Canada, and Europe for the rare disease, diffuse cutaneous systemic sclerosis (dcSSc)

Mar 19, 2021: Cantargia reports positive preclinical safety and efficacy results in the CAN10 project

Mar 11, 2021: Vicore Pharma’s drug candidate C21 dilates peripheral resistance vessels in fibrotic disease

Mar 04, 2021: Genentech’s Actemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults With systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Frequently asked questions

Systemic Sclerosis (Scleroderma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Systemic Sclerosis (Scleroderma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Systemic Sclerosis (Scleroderma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.